Incyte completes acquisition of Vega Therapeutics from Star Therapeutics

Incyte announced on July 6, 2026 that it had completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC.¹ The deal brings in VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder.¹

Mechanistically, VGA039 acts on Protein S as a way to help restore normal clotting function and reduce bleeding across a range of bleeding disorders.¹ The drug is currently being tested in a trial called the "Phase 3 VIVID-6 study (NCT07115004)," a global single-arm cross-over study evaluating the safety and efficacy of subcutaneous VGA039 as prophylaxis for bleeding across all VWD subtypes, including patients with high disease burden.¹ If cleared by regulators, Incyte said VGA039 could become the first once-monthly subcutaneous prophylactic option for VWD patients, who currently rely on frequent intravenous infusions.¹

The FDA has already granted the compound Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations.¹

On deal terms, Incyte acquired all outstanding shares of Vega Therapeutics for $1.25 billion paid upfront,¹ and Star Therapeutics could receive up to $750 million more tied to future sales milestones.¹ Incyte said it expects to record the acquisition cost as a one-time research and development charge affecting both third-quarter and full-year 2026 results, under GAAP and non-GAAP reporting.¹

Advisors on the transaction included Lazard as financial advisor and Goodwin Procter LLP as legal counsel to Incyte,¹ while Evercore and Morgan Stanley advised Star Therapeutics, with Fenwick & West LLP serving as its legal counsel.¹